Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of 10, 20, 40 and 60 mg oral PRAX-114 compared to placebo in the treatment of adults with MDD. The study will enroll participants on adjunctive treatment who had an inadequate response to their current antidepressant treatment and participants not currently being treated with pharmacotherapy for MDD. A sub-study to investigate the pharmacokinetics (PK) of PRAX-114 and metabolites when dosed in the evening in participants with MDD will be conducted in a subset of participants at selected research sites with serial PK sampling capabilities.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PRAX-114 (10 mg) | Experimental | 10 mg PRAX-114 once daily |
|
| PRAX-114 (20 mg) | Experimental | 20 mg PRAX-114 once daily |
|
| PRAX-114 (40 mg) | Experimental | 40 mg PRAX-114 once daily |
|
| PRAX-114 (60 mg) | Experimental | 60 mg PRAX-114 once daily |
|
| Placebo | Placebo Comparator | Placebo once daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 10 mg PRAX-114 | Drug | Once daily oral treatment |
| |
| 20 mg PRAX-114 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in HAM-D17 total score at Day 15 | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 15 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in HAM-D17 total score at Day 29 | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and severity of Adverse Events (AE) | An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study drug, whether or not considered related to the study drug. | 43 days |
| Incidence of AEs by preferred term |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Executive Director Clinical Development | Praxis Precision Mediciines | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Praxis Research Site | Lafayette | California | 94549 | United States | ||
| Praxis Research Site |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Once daily oral treatment |
|
| 40 mg PRAX-114 | Drug | Once daily oral treatment |
|
| 60 mg PRAX-114 | Drug | Once daily oral treatment |
|
| Placebo | Drug | Once daily oral treatment |
|
| 29 days |
| Change from baseline in HAM-D17 total score at all other time points | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 4 days, 8 days, 22 days, 36 days, and 43 days |
| Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points | The CGI-S assesses the clinician's impression of the participant's current depression symptoms. The clinician should use his/her total clinical experience with this patient population and rate the current severity of the participant's mental illness on a 7-point scale from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
| Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points | The CGI-I assesses the participant's improvement (or worsening). The clinician is required to assess the participant's condition relative to Baseline (Day 1) on a 7-point scale from 1 (Very much improved) to 7 (Very much worse). | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
| HAM-D17 response (reduction from baseline score of ≥50%) at Day 15, Day 29, and all other time points | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
| HAM-D17 remission (total score of ≤7) at Day 15, Day 29, and all other time points | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
| Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points | The SDQ is a 44-item, self-report scale assessing the severity of symptoms across several subtypes of depression. Items are scored on a 7-point scale (ranging from 1 to 6). The SDQ total score is the sum of all 44 item scores and ranges from 44 to 264 with higher scores indicating worse symptoms. | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
| Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points | The PGI-I scale is a global self-assessment used to rate the response of a participant's condition to therapy or intervention. It consists of 1 question that asks the participant to rate their current condition compared to how it was prior to beginning treatment on a scale of 1 (very much better) to 7 (very much worse). | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
| Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points | The WSAS assesses the degree to which mental health problems interfere with day-to-day functioning in 5 domains: work, social leisure activities, private leisure activities, home- management, and personal relationships. The WSAS total score is the sum of the 5 item scores and ranges from 0 to 40, with higher scores indicating poorer adjustment. | 4 days, 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days |
The incidence of AEs will be reported by preferred term, including any terms related to clinically significant changes in body temperature, pulse rate, respiratory rate, blood pressure (systolic and diastolic), clinical laboratory measures (chemistry, hematology, urinalysis, and coagulation), and electrocardiogram parameters (heart rate, PR, QRS, QT, and corrected QT intervals). |
| 43 days |
| Incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) measured suicidal ideation or behavior | The C-SSRS is composed of 5 yes/no questions addressing suicidal behavior and 5 yes/no questions addressing suicidal ideation, with sub-questions assessing the severity. Incidence is measured as the number of "yes" answers indicating the presence of suicidal ideation or behavior. | 43 days |
| Lemon Grove |
| California |
| 91945 |
| United States |
| Praxis Research Site | Oceanside | California | 92056 | United States |
| Praxis Research Site | Redlands | California | 92374 | United States |
| Praxis Research Site | Jacksonville | Florida | 32256 | United States |
| Praxis Research Site | Orange City | Florida | 32763 | United States |
| Praxis Research Site | Orlando | Florida | 32801 | United States |
| Praxis Research Site | Atlanta | Georgia | 30331 | United States |
| Praxis Research Site | Decatur | Georgia | 30030 | United States |
| Praxis Research Site | Gaithersburg | Maryland | 20877 | United States |
| Praxis Research Site | Boston | Massachusetts | 02131 | United States |
| Praxis Research Site | Worcester | Massachusetts | 01655 | United States |
| Praxis Research Site | O'Fallon | Missouri | 63368 | United States |
| Praxis Research Site | Las Vegas | Nevada | 89102 | United States |
| Praxis Research Site | Cedarhurst | New York | 11516 | United States |
| Praxis Research Site | Rochester | New York | 14618 | United States |
| Praxis Research Site | Dayton | Ohio | 45417 | United States |
| Praxis Research Site | Allentown | Pennsylvania | 18104 | United States |
| Praxis Research Site | Media | Pennsylvania | 19063 | United States |
| Praxis Research Site | Memphis | Tennessee | 38119 | United States |
| Praxis Research Site | Austin | Texas | 78737 | United States |
| Praxis Research Site | Charlottesville | Virginia | 22903 | United States |
| Praxis Research Site | Everett | Washington | 98201 | United States |
| Praxis Research Site | Noble Park | Victoria | 3174 | Australia |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 1, 2024 | Mar 26, 2024 | 8 |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D019964 | Mood Disorders |
| D003866 | Depressive Disorder |
| D003863 | Depression |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided